How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,550 results for

Crust

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2501. Herpes zoster treatments: results of a clinical trial relative to the use of rifamycin SV versus neuramide. (PubMed)

by both treatments but statistical tests revealed that rifamycin SV was able to heal pain (p less than 0.05), vesicles, crusts and burning sensation (p less than 0.1) faster than neuramide. Furthermore, by the seventh day of therapy, the authors found that rifamycin SV reduced the intensity of both pain and erythema (p less than 0.01 for pain; p less than 0.05 for erythema) more than neuramide.

1984 The Journal of international medical research

2502. Topical acyclovir in the treatment of genital herpes: a comparison with systemic therapy. (PubMed)

Topical acyclovir in the treatment of genital herpes: a comparison with systemic therapy. Controlled trials of acyclovir cream were conducted in the treatment of initial and recurrent genital herpes. For 54 patients with the first episode of genital infection (initial disease) treated with acyclovir the duration of viral shedding, formation of new lesions, times to crusting and healing and duration of symptoms were significantly reduced compared with the results obtained in 47 placebo

1983 The Journal of antimicrobial chemotherapy

2503. Vidarabine therapy for mucocutaneous herpes simplex virus infections in the immunocompromised host. (PubMed)

population as assessed by loss of virus from lesions, cessation of lesion formation, and time to crusting. Group A patients demonstrated accelerated loss of pain from lesions (P = 0.0099) and defervescence (P = 0.03). Patients in group A who had HSV type 1 (HSV-1) infections or who were over 40 years of age did clear virus from lesions more rapidly (P = 0.04 and P = 0.03, respectively). No toxicity or significant adverse effects could be attributed to vidarabine administration. Benefit from vidarabine

1984 The Journal of infectious diseases

2504. Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections. (PubMed)

of local pain or itching, 3.6 days, and mean time to healing of lesions, 11.2 days, were less than in placebo recipients 4.6, 6.7, and 15.8 days, respectively (p less than 0.05 for each comparison). Among patients with recurrent genital herpes, the mean duration of viral shedding from genital lesions was 0.8 days in acyclovir recipients compared with 1.7 days in placebo recipients (p less than 0.001). Among men with recurrent genital herpes, the mean time to crusting and healing of lesions was 3.5

1982 The American journal of medicine

2505. Oral acyclovir in the treatment of genital herpes. Preliminary report of a multicenter trial. (PubMed)

patients with initial disease who received acyclovir had a shorter median duration in days of viral shedding (1.0), pain (3.5), combined symptoms (3.5), time to crusting (3.5), and time to complete healing (5.5) than the 11 culture-positive placebo recipients whose scores were 8.0, 4.5, 4.5, 9.0, and 11.0 respectively (p less than 0.05 for all comparisons). Patients with recurrent disease receiving acyclovir also experienced a reduction in the median duration in days of viral shedding (0.5), time (...) to crusting (men only) (3.0), and time to complete healing (5.0), compared with 2.5, 4.0, and 7.0 days, respectively, for control patients (p less than 0.01 for each variable). New lesion formation was effectively prevented by acyclovir in patients with both initial and recurrent infections (p less than 0.05). Oral acyclovir therapy was well-tolerated and shortened the course of both initial and recurrent genital herpes.

1982 The American journal of medicine

2506. Successful treatment of herpes labialis with topical acyclovir. (PubMed)

Successful treatment of herpes labialis with topical acyclovir. A double blind, placebo controlled trial of 5% acyclovir cream, applied topically five times a day for five days, was carried out in 49 patients with recurrent herpes labialis. These patients had a total of 74 episodes, 34 of which were treated with the 5% acyclovir cream and 40 with matching placebo. First episodes and all episodes treated with acyclovir cream had significantly shorter times to formation of ulcer or crust

Full Text available with Trip Pro

1983 British medical journal (Clinical research ed.)

2507. Bacteriology and treatment of purulent nasopharyngitis: a double blind, placebo-controlled evaluation. (PubMed)

comparable with regard to age, sex, race, number of patients withdrawn from the study, fever greater than 38.0 degrees C, appearance of nasal discharge, nasal crusting and number of days until follow-up. Initial cultures from patients grew: Streptococcus pneumoniae, 46%; Haemophilus influenzae type b, 21%; and Streptococcus pyogenes, 8%. Nasal crusting was significantly associated with the growth of S. pneumoniae or H. influenzae type b. There were no significant differences between active drug

1984 Pediatric infectious disease

2508. Oral acyclovir for herpes zoster: a double-blind controlled trial in normal subjects. (PubMed)

Oral acyclovir for herpes zoster: a double-blind controlled trial in normal subjects. Sixty immunocompetent patients with herpes zoster of various dermatomes were treated 5 times a day for 5 days with either acyclovir at a dose of 400 mg or placebo. Acyclovir was shown to reduce significantly the time to full crusting (P = 0.02). There were also trends in favour of acyclovir for time to first dry vesicle and time to first day without macules or papules, but these were not statistically

1987 The British journal of dermatology

2509. Therapy of genital herpes with topically applied interferon. (PubMed)

Therapy of genital herpes with topically applied interferon. Ninety-four patients with recurrences of genital herpes were randomized in a double-blind trial to receive topical therapy for 5 days with either alpha-2a interferon at 30 X 10(6) IU/ml or 10 X 10(6) IU/ml or placebo six times daily. No differences were noted between either interferon dose and placebo with respect to the duration of viral shedding, the time to crusting, or the time to healing of herpetic lesions. Aqueous solutions

Full Text available with Trip Pro

1987 Antimicrobial agents and chemotherapy

2510. Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study. (PubMed)

Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study. A study of the effects of oral acyclovir (200 mg), administered five times per day for 5 days in 210 patients who cultured positive for herpes labialis, is made. A total of 149 patients were followed through three episodes each of herpes labialis while taking a placebo or acyclovir. Patients were evaluated for several clinical parameters, including the loss of lesion crust and reduction of the size

1987 Journal of the American Dental Association

2511. Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial. (PubMed)

all patients on entry to the study and on Day 21 to determine presence or absence of antibodies to HSV-1 and HSV-2. Time to healing, time to crusting, time to cessation of viral shedding, and appearance of new lesions during therapy were compared for each treatment group.Patients receiving acyclovir experienced a significant reduction in the median duration of pain (4.3 versus 4.8 days, p = 0.019), viral shedding (1.9 versus 8.4 days, p less than 0.001), and time to healing (8.4 versus 11.5 days

1988 The American journal of medicine

2512. Efficacy of oral acyclovir treatment of acute herpes zoster. (PubMed)

), and full crusting (p = 0.03). No significant hastening of rash healing was seen in those who started therapy later than 48 hours after the onset of rash. There was also a significant reduction pain during treatment with acyclovir (p = 0.02). Acyclovir produced no effects on the frequency or severity of post-herpetic neuralgia. No clinically important adverse effects of acyclovir were reported.

1988 The American journal of medicine

2513. Current therapy of varicella zoster virus infection in immunocompromised patients. A comparison of acyclovir and vidarabine. (PubMed)

positive and new lesions formed. Acyclovir also shortened the median interval until the first decrease in pain, the crusting of all lesions, and the complete healing of lesions. Acyclovir is more effective than vidarabine in the treatment of VZV infection in severely immunocompromised patients and should be considered the treatment of choice in such cases.

1988 The American journal of medicine

2514. Treatment of impetigo and ecthyma. A comparison of sulconazole with miconazole. (PubMed)

, bacterial cultures from 26 (69%) were negative by treatment day 4, and those from all 32 (100%) were negative by treatment day 7; among the 34 miconazole-treated impetigo patients, cultures from 17 (50%) were negative by treatment day 4, cultures from 32 (94.1%) were negative by treatment day 7, and cultures from 29 (97%) were negative by treatment day 14. Each treatment promptly relieved the pyodermal signs (crusts, vesicles, pustules, bullae, and exudate). Both agents were considered to be safe

1988 International journal of dermatology

2515. Acyclovir prevents dissemination of varicella in immunocompromised children. (PubMed)

who did not receive open treatment, acyclovir significantly reduced time to full crusting (P = .01). Overall, acyclovir, as judged by the physician, significantly improved the patients' condition.

1988 The Journal of infectious diseases

2516. Evaluation of the efficacy of topical bufexamac in epidermolysis bullosa simplex. A double-blind placebo-controlled crossover trial. (PubMed)

with ten patients (nine, Weber-Cockayne variant; one, generalized EB simplex). Each of the two preparations was applied four times daily during the 2 four-week treatment periods. Weekly assessments included counts of blisters, crusts, and erosions, and assessments of alterations in cutaneous pain, healing times, and activity times before further blister formation. Although considerable variability in individual responses was noted, no significant difference was detectable between the active drug

1988 Archives of Dermatology

2517. Success of balloon catheter dilatation as a primary or secondary procedure for congenital nasolacrimal duct obstruction. (PubMed)

resolution of signs and symptoms (crusting, discharge, and increased tear meniscus). Age, inferior turbinate infracture, and Downe's syndrome as related to the main outcome measure were also analyzed.Overall, 56 of the 73 lacrimal systems (76.7%) had complete resolution of symptoms. Twenty-seven of all 34 primary balloon catheter dilatations (79.4%) remained clinically patent, whereas 29 of all 39 secondary balloon catheter dilatations (74.4%) remained clinically patent after surgery (P = 0.8165). Thirty

2002 Ophthalmology

2518. Scabies and pediculosis pubis: an update of treatment regimens and general review. (PubMed)

be of particular use in institutional outbreaks and in communities in which scabies is endemic. Combination treatment with topical agents and oral ivermectin may be necessary for crusted scabies. Treatment of pediculosis pubis is best accomplished with topical permethrin, lindane, or pyrethrins with piperonyl butoxide. Although resistance to these topical agents has been reported in head lice, decreased efficacy in the treatment of pediculosis pubis has not been reported.

Full Text available with Trip Pro

2002 Clinical Infectious Diseases

2519. Practical aspects on rhinostereometry. (PubMed)

the need to use a tooth splint, the indoor climate, hairs of the vestibulum, psychological influence, anatomical variations, secretion, crusts, subjective interpretation by the observer, and positioning time are important for obtaining consensus recommendations in rhinostereometry studies.

2002 Rhinology

2520. Blindness following medial maxillectomy. (PubMed)

Blindness following medial maxillectomy. Medial maxillectomy via lateral rhinotomy approach is used in the treatment for tumours affecting the lateral nasal wall. The most frequent complications are crusting, epicanthal scarring and epiphora. The authors report a rare case of blindness secondary to indirect optic neuropathy following medial maxillectomy undertaken to treat a malignant melanoma arising in the lateral nasal wall. It is important to keep in mind, the possibility of this rare

2002 Rhinology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>